-
Exenatide, sold
under the
brand name
Byetta among others, is a
medication used to
treat type 2 diabetes. It is used
together with diet, exercise, and...
- the
exception of insulin, most GLP-1
receptor agonists (liraglutide,
exenatide, and others), and pramlintide, all
diabetes medications are administered...
-
version of exendin-4
called exenatide. In 2002, Eli
Lilly entered into an
alliance with
Amylin to
further develop exenatide and
secure official approval...
-
pancreatitis including metformin, but glucagon-like peptide-1
mimetics such as
exenatide are more
strongly ****ociated with
pancreatitis by
promoting inflammation...
-
produced three drugs:
Symlin (pramlintide acetate),
Byetta (
exenatide) and
Bydureon (
exenatide extended release). In 1987,
Amylin Pharmaceuticals was co-founded...
- agonists. In 2005, the U.S. Food and Drug
Administration approved the drug
exenatide (marketed as Byetta) for the
management of type 2 diabetes. It is a synthetic...
-
insulin product in the U.S.,
Basaglar (insulin glargine).
Lilly brought exenatide to market—the
first of the GLP-1
receptor agonists—followed by blockbuster...
- with
liraglutide 1.8 mg
compared to
insulin glargine, 0.33% more than
exenatide 10 μg
twice daily,
sitagliptin and rosiglitazone. In a
randomized controlled...
- the risk of thrombosis. It is an
antagonist of
glycoprotein IIb/IIIa.
Exenatide is a 39-amino-acid
peptide that is a
synthetic version of exendin-4, a...
-
three years of use of glucagon-like peptide-1
receptor agonists like
exenatide, liraglutide, and
dulaglutide may be
linked with
increased occurrence...
